CDK 4/6 inhibitor blocks proliferation in an RB- and cyclin D-dependent manner in preclinical prostate cancer models, raising the hypothesis that co-targeting AR and cell cycle with CDK 4/6 inhibitor could improve outcomes in patients with mHSPC. This evidence concerns the gene RB1 and prostate carcinoma.